Completed PHASE3 INTERVENTIONAL 2-arm NCT01024413

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

A Randomized, Controlled Phase III Trial to Evaluate the Efficacy of Elortinib vs Gefitinib in Advanced Non-small-cell Lung Cancer With EGFR Exon 19 or 21 Mutations

Sponsor: Chinese Society of Lung Cancer

Conditions Thoracic Neoplasms

Interventions erlotinib gefitinib

Updated 8 times since 2017 Last updated: Feb 28, 2017 Started: Jul 31, 2009 Primary completion: Jun 30, 2015 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Thoracic Neoplasms and is currently completed. Chinese Society of Lung Cancer leads this study, which shows 8 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Dec 2019 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Dec 2019 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Mar 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Mar 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese Society of Lung Cancer
Guangdong Provincial People's Hospital

Data source: Chinese Society of Lung Cancer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China